Tara Beaulieu1, Kanna Hayashi1,2,3, Michael J Milloy1,2,4, Ekaterina Nosova1,2, Kora DeBeck1,2,5, Julio Montaner1,4, Thomas Kerr1,2,4, Lianping Ti1,4. 1. Department of Epidemiology and Population Health, British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, British Columbia, Canada. 2. British Columbia Centre on Substance Use, St. Paul's Hospital, Vancouver, British Columbia, Canada. 3. Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada. 4. Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 5. School of Public Policy, Simon Fraser University, Vancouver, British Columbia, Canada.
Abstract
BACKGROUND: People who inject drugs (PWIDs) and who are living with HIV and hepatitis C virus (HCV) infection are vulnerable to a range of health-related harms, including liver cirrhosis, hepatocellular carcinoma, and death. There is limited evidence describing how HIV serostatus shapes access to a physician for regular HCV care among PWID. SETTING: Data were collected through the Vancouver Injection Drug Users Study (VIDUS), the AIDS Care Cohort to evaluate Exposure to Survival Services (ACCESS), and the At-Risk Youth Study (ARYS), 3 prospective cohorts involving people who use illicit drugs in Vancouver, Canada, between 2005 and 2015. METHODS: Using generalized estimating equations, we examined the relationship between HIV-seropositivity and having access to a physician for regular HCV care. We conducted a mediation analysis to examine whether this association was mediated by increased frequency of engagement in health care. RESULTS: In total, 1627 HCV-positive PWID were eligible for analysis; 582 (35.8%) were HIV-positive at baseline; and 31 (1.9%) became HIV-positive during follow-up. In multivariable analyses, after adjusting for a range of confounders, HIV serostatus [adjusted odds ratio = 1.99; 95% confidence interval: 1.77 to 2.24] was significantly associated with having access to HCV care. Approximately 26% of the effect was due to mediation. CONCLUSION: Our results demonstrate a positive relationship between HIV-seropositivity and having access to a physician for regular HCV care, which is partially explained through increased frequency of engagement in health care. These findings highlight the need to address patterns of inequality in access to HCV care among PWID.
BACKGROUND:People who inject drugs (PWIDs) and who are living with HIV and hepatitis C virus (HCV) infection are vulnerable to a range of health-related harms, including liver cirrhosis, hepatocellular carcinoma, and death. There is limited evidence describing how HIV serostatus shapes access to a physician for regular HCV care among PWID. SETTING: Data were collected through the Vancouver Injection Drug Users Study (VIDUS), the AIDS Care Cohort to evaluate Exposure to Survival Services (ACCESS), and the At-Risk Youth Study (ARYS), 3 prospective cohorts involving people who use illicit drugs in Vancouver, Canada, between 2005 and 2015. METHODS: Using generalized estimating equations, we examined the relationship between HIV-seropositivity and having access to a physician for regular HCV care. We conducted a mediation analysis to examine whether this association was mediated by increased frequency of engagement in health care. RESULTS: In total, 1627 HCV-positive PWID were eligible for analysis; 582 (35.8%) were HIV-positive at baseline; and 31 (1.9%) became HIV-positive during follow-up. In multivariable analyses, after adjusting for a range of confounders, HIV serostatus [adjusted odds ratio = 1.99; 95% confidence interval: 1.77 to 2.24] was significantly associated with having access to HCV care. Approximately 26% of the effect was due to mediation. CONCLUSION: Our results demonstrate a positive relationship between HIV-seropositivity and having access to a physician for regular HCV care, which is partially explained through increased frequency of engagement in health care. These findings highlight the need to address patterns of inequality in access to HCV care among PWID.
Authors: S A Strathdee; A Palepu; P G Cornelisse; B Yip; M V O'Shaughnessy; J S Montaner; M T Schechter; R S Hogg Journal: JAMA Date: 1998-08-12 Impact factor: 56.272
Authors: Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore Journal: Int J Drug Policy Date: 2015-07-17
Authors: Mark Hull; Stephen Shafran; Alex Wong; Alice Tseng; Pierre Giguère; Lisa Barrett; Shariq Haider; Brian Conway; Marina Klein; Curtis Cooper Journal: Can J Infect Dis Med Microbiol Date: 2016-07-04 Impact factor: 2.471
Authors: Alexandra B Collins; Surita Parashar; Robert S Hogg; Saranee Fernando; Catherine Worthington; Patrick McDougall; Rosalind Baltzer Turje; Ryan McNeil Journal: J Int AIDS Soc Date: 2017-03-03 Impact factor: 5.396
Authors: Vivian F Go; Giuliana J Morales; Nguyen Tuyet Mai; Ross C Brownson; Tran Viet Ha; William C Miller Journal: Implement Sci Date: 2016-04-20 Impact factor: 7.327
Authors: Janice L Clarke; Scott Bourn; Alexis Skoufalos; Eric H Beck; Daniel J Castillo Journal: Popul Health Manag Date: 2016-08-26 Impact factor: 2.459
Authors: Yun-Chi Chen; Chloe L Thio; Andrea L Cox; Sebastian Ruhs; Farin Kamangar; Kjell J Wiberg Journal: BMJ Open Date: 2019-03-30 Impact factor: 2.692
Authors: Oluwaseun Falade-Nwulia; Rachel E Gicquelais; Jacquie Astemborski; Sean D McCormick; Greg Kirk; Mark Sulkowski; David L Thomas; Shruti H Mehta Journal: Liver Int Date: 2020-10 Impact factor: 8.754